StockMacro
Company, fund or insider

Help

Menu

Daxor

$7.45 -29% in 6 monthsMarket cap $43.5M

DXR on XNAS, Health Care, Daxor Corporation, job postings

Measures activity, not value. Not investment advice.

Shares fell 43% in a year while insiders bought $8K and sold nothing.

  • BadDown 24% in one month and 31% in six months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. The company operates as a single business segment centered on the development, commercialization, and support of its proprietary blood volume analysis technology used by healthcare providers.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
750
Website
daxor.com
Listed
Nasdaq, US

No income statement in this company's recent SEC filings in our data (it may report under IFRS, in another currency, or not file with the SEC).

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
DaxorDXR (this company) $43.5M––––
RenovoRxRNXT $45.5Mloss16.4–-469%
Microbot MedicalMBOT $45.7Mloss–––
Sensus HealthcareSRTS $37.2Mloss2.2-53%-96.5%
LensarLNSR $54.8M–0.91+1.6%56.1%
Spectral AIMDAI $33.5Mloss2.3-38%-70.5%

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$8K

bought $8K, sold $0

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

1,022 shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

1,022 shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-70%

3,374 shares sold short in the report before, 1,022 on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

44%

44% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 36%

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

10

10 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

10 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $7.45 on 20 Nov 2026, -43% over 12 months (12-month range $7.45 to $14.75)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $27K in the last 12 months (the 12 months before: $63K).
Institutional holders (13F filers). 19 13F filers reported holding it in the latest 13F quarter, +217% on a year earlier.
Federal obligations. Federal obligations: $5K published in the last 12 months, 0% on the 12 months before.
Lobbying spend. Lobbying spend: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, revenue per quarter, capital spending per quarter, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
5 Jun 20248-K and other filingsDelisting notice or listing transfer
29 Sep 2023Sharp changeFirst federal award: first federal award: DAXOR CORPORATION: new Department of Defense contract HT942523C0050 ($1,099,997)
20 Apr 2023Lobbying filinglobbying engagement terminated (STRATEGIC MARKETING INNOVATIONS)
18 Apr 2022Lobbying filingnew lobbying registration (STRATEGIC MARKETING INNOVATIONS)
24 Jan 20228-K and other filingsDirector or officer change
24 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jan 20228-K and other filingsDelisting notice or listing transfer
Insider net buying (open market)
Month from 1 Nov 2022: $40K published
Month from 1 May 2023: $22K published
Month from 1 Oct 2023: $5K published
Month from 1 Nov 2023: $15K published
Month from 1 Dec 2023: $9K published
Month from 1 Mar 2024: $14K published
Month from 1 Dec 2024: $0 published
Month from 1 Mar 2025: $47K published
Month from 1 Apr 2025: $16K published
Month from 1 Nov 2025: $0 published
Month from 1 Dec 2025: $0 published
Month from 1 Mar 2026: $0 published
Month from 1 Apr 2026: $19K published
Month from 1 Nov 2026: $8K published
Institutional holders (13F filers)
31 Dec 2021 report: 6; public on 14 Feb 2022
31 Mar 2022 report: 5; public on 16 May 2022
30 Jun 2022 report: 5; public on 15 Aug 2022
30 Sep 2022 report: 5; public on 14 Nov 2022
31 Dec 2022 report: 5; public on 14 Feb 2023
31 Mar 2023 report: 4; public on 15 May 2023
30 Jun 2023 report: 5; public on 14 Aug 2023
30 Sep 2023 report: 4; public on 14 Nov 2023
31 Dec 2023 report: 6; public on 14 Feb 2024
31 Mar 2024 report: 7; public on 15 May 2024
30 Jun 2024 report: 6; public on 14 Aug 2024
30 Sep 2024 report: 9; public on 14 Nov 2024
31 Dec 2024 report: 9; public on 14 Feb 2025
31 Mar 2025 report: 7; public on 15 May 2025
30 Jun 2025 report: 6; public on 14 Aug 2025
30 Sep 2025 report: 6; public on 14 Nov 2025
31 Dec 2025 report: 8; public on 17 Feb 2026
31 Mar 2026 report: 14; public on 15 May 2026
30 Jun 2026 report: 14; public on 14 Aug 2026
30 Sep 2026 report: 19; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $50K published
Month from 1 Feb 2022: $0 published
Month from 1 Mar 2022: $0 published
Month from 1 Apr 2022: $0 published
Month from 1 Jul 2022: $55K published
Month from 1 Aug 2022: $5K published
Month from 1 Nov 2022: $0 published
Month from 1 Jul 2023: -$50K published
Month from 1 Aug 2023: $5K published
Month from 1 Sep 2023: $1.1M published
Month from 1 Oct 2023: $305K published
Month from 1 Nov 2023: $0 published
Month from 1 Jun 2024: $0 published
Month from 1 Jul 2024: $5K published
Month from 1 Nov 2024: $2.4M published
Month from 1 Jun 2025: $0 published
Month from 1 Jul 2025: $5K published
Month from 1 Jun 2026: $0 published
Month from 1 Aug 2026: $5K published
Lobbying spend
Quarter from 1 Jul 2022: $30K published
Quarter from 1 Oct 2022: $10K published
Quarter from 1 Jan 2023: $20K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 19 (30 Sep 2026), 2.7× its normal reading; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $27K in the last 12 months (the 12 months before: $63K).
  • Institutional holders (13F filers): 19 13F filers reported holding it in the latest 13F quarter, +217% on a year earlier.
  • Federal obligations: Federal obligations: $5K published in the last 12 months, 0% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 53 insider trades

Last 90 days: no sales; 1 purchase, $8K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Robert J MichelChief Financial OfficerBuy1,000$8.03$8KForm 4
10 Apr 2026Michael Richard FeldschuhChief Executive OfficerBuy1,000$9.07$9KForm 4
31 Mar 2026Robert J MichelChief Financial OfficerBuy1,000$9.90$10KForm 4
7 Apr 2025Michael Richard FeldschuhChief Executive OfficerBuy2,063$7.89$16KForm 4
27 Mar 2025Michael Richard FeldschuhChief Executive OfficeBuy1,000$8.13$8KForm 4
20 Mar 2025Michael Richard FeldschuhChief Executive OfficerBuy647$8.15$5KForm 4
11 Mar 2025Robert J MichelChief Financial OfficerBuy1,000$8.00$8KForm 4
11 Mar 2025Michael Richard FeldschuhChief Executive OfficerBuy3,360$7.68$26KForm 4

19 institutions reported shares at the end of Q3 2026, 11% of the shares outstanding; 4 opened a position, 0 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Thompson Siegel & Walmsley LLC242K5.76%No change
Vanguard Capital Management LLC49K1.17%$545K+277+0.6%
Aristides Capital LLC42K0.99%$469KNo change
BFC Planning, Inc.34K0.80%$379K-3,000-8.2%
Renaissance Technologies LLC30K0.70%$332K+100+0.3%
HRT Financial LP15K0.37%New+15K
Susquehanna International Group, LLP15K0.37%$171K-12K-43%
Nano Cap New Millennium Growth Fund L P15K0.36%$169K+2,500+20%
Crescent Grove Advisors, LLC12K0.30%$140KNo change
SBI Securities Co., Ltd.3,1310.07%$35KNo change

Federal contracts

All 2 federal contracts

No new award in 12 months; the latest was signed 1 Aug 2024. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
1 Aug 2024Department of DefenseDepartment of the Air Force$1.9M59 MDW/ST SBIR II TACFI. DEVELOP AND VALIDATE HARDWARE AND METHOD FOR THE BVA-200F DIAGNOSTIC.USAspending
29 Jun 2023Department of DefenseDefense Health Agency$1.1MDHA SBIR PH II H2S-0039 (MONTHS 1-23)USAspending

Company events

All 9 company events

In 12 months: 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
26 Jan 2026Signed a major agreement8-K
5 Jun 2024Delisting notice or listing transfer8-K
24 Jan 2022Director or officer change8-K
20 Jan 2022Delisting notice or listing transfer8-K
1 Jul 2020Director or officer changeSame filing: shareholder vote results8-K
28 Sep 2018Director or officer change8-K
16 Feb 2017Director or officer change8-K
22 Sep 2016Director or officer change8-K

Reported lobbying spend: $20K in Q4 2022, $10K in Q3 2022. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Jan 2023EndedStrategic Marketing Innovationsfor Daxor CorporationNot statedFiling
24 Mar 2022NewStrategic Marketing Innovationsfor Daxor CorporationFunding for medical diagnosticDefenseFiling
30 Sep 2018EndedK&L Gates, LLPfor Daxor CorporationNot statedFiling
11 Jan 2017NewK&L Gates, LLPfor Daxor CorporationDiagnostic health care device for use in veteran and military populations.Health issues, Defense, VETFiling
31 Dec 2015EndedFoley & Lardner LLPfor Daxor CorporationNot statedFiling
12 Jun 2015NewFoley & Lardner LLPfor Daxor CorporationFDA inspection issueHealth issuesFiling

The 5 newest of 15 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 19 Nov 2026Insiders record

    Michel Robert J (Chief Financial Officer) bought 1,000 shares of DXR ($8,030)

  2. 11 Apr 2026Insiders record

    Feldschuh Michael Richard (Chief Executive Officer) bought 1,000 shares of DXR ($9,070) (dated 10 Apr 2026)

  3. 1 Apr 2026Insiders record

    Michel Robert J (Chief Financial Officer) bought 1,000 shares of DXR ($9,900) (dated 31 Mar 2026)

  4. 25 Mar 2026Insiders record

    Jefferies John (Chief Medical Officer) bought 5,941 shares of DXR [not an open-market trade] (dated 24 Mar 2026)

  5. 12 Dec 2025Insiders record

    Feldschuh Jonathan Adam (Chief Scientific Officer) bought 18,000 shares of DXR [not an open-market trade] (dated 11 Dec 2025)

  6. 12 Dec 2025Insiders record

    Michel Robert J (Chief Financial Officer) bought 3,000 shares of DXR [not an open-market trade] (dated 11 Dec 2025)

  7. 15 Nov 2025Insiders record

    Jefferies John (Chief Medical Officer) bought 2,344 shares of DXR [not an open-market trade] (dated 14 Nov 2025)

  8. 8 Apr 2025Insiders record

    Feldschuh Michael Richard (Chief Executive Officer) bought 2,063 shares of DXR ($16,277) (dated 7 Apr 2025)

  9. 28 Mar 2025Insiders record

    Feldschuh Michael Richard (Chief Executive Office) bought 1,000 shares of DXR ($8,130) (dated 27 Mar 2025)

  10. 21 Mar 2025Insiders record

    Feldschuh Michael Richard (Chief Executive Officer) bought 647 shares of DXR ($5,273) (dated 20 Mar 2025)

  11. 21 Mar 2025Insiders record

    Feldschuh Michael Richard (Chief Executive Officer) bought 1,492 shares of DXR ($11,518) [amended] (dated 20 Mar 2025)

  12. 12 Mar 2025Insiders record

    Michel Robert J (Chief Financial Officer) bought 1,000 shares of DXR ($8,000) (dated 11 Mar 2025)

  13. 12 Mar 2025Insiders record

    Feldschuh Michael Richard (Chief Executive Officer) bought 3,360 shares of DXR ($25,805) (dated 11 Mar 2025)

  14. 11 Dec 2024Insiders record

    Feldschuh Jonathan Adam (Chief Scientific Officer) bought 32,000 shares of DXR [not an open-market trade] (dated 10 Dec 2024)

  15. 11 Dec 2024Insiders record

    Michel Robert J (Chief Financial Officer) bought 4,750 shares of DXR [not an open-market trade] (dated 10 Dec 2024)

  16. 11 Dec 2024Insiders record

    Feldschuh Michael Richard (Chief Executive Officer) bought 45,000 shares of DXR [not an open-market trade] (dated 10 Dec 2024)

  17. 1 Nov 2024Government contracts record

    DAXOR CORPORATION: new Department of Defense contract FA301624P0153 ($1.9M) (dated 1 Aug 2024)

  18. 5 Jun 2024Filings record

    Delisting notice or listing transfer

  19. 28 Mar 2024Insiders record

    Michel Robert J (Chief Financial Officer) bought 750 shares of DXR ($6,525) (dated 27 Mar 2024)

  20. 7 Mar 2024Insiders record

    Feuer Edward (director) bought 1,000 shares of DXR ($7,210) (dated 6 Mar 2024)

  21. 7 Dec 2023Insiders record

    Michel Robert J (Chief Financial Officer) bought 120 shares of DXR ($930) (dated 6 Dec 2023)

  22. 2 Dec 2023Insiders record

    Michel Robert J (Chief Financial Officer) bought 180 shares of DXR ($1,395) (dated 1 Dec 2023)

  23. 2 Dec 2023Insiders record

    Feldschuh Michael Richard (Chief Executive Officer) bought 800 shares of DXR ($6,240) (dated 1 Dec 2023)

  24. 28 Nov 2023Insiders record

    Michel Robert J (Chief Financial Officer) bought 500 shares of DXR ($3,970) (dated 27 Nov 2023)

  25. 14 Nov 2023Insiders record

    Feldschuh Michael Richard (CHIEF EXECUTIVE OFFICER) bought 1,402 shares of DXR ($10,986) (dated 13 Nov 2023)

  26. 17 Oct 2023Insiders record

    Michel Robert J (Chief Financial Officer) bought 500 shares of DXR ($4,510) (dated 16 Oct 2023)

  27. 29 Sep 2023Government contracts change

    won its first federal award in our data, a $1.1M Department of Defense contract.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  28. 29 Sep 2023Government contracts record

    DAXOR CORPORATION: new Department of Defense contract HT942523C0050 ($1.1M) (dated 29 Jun 2023)

  29. 26 May 2023Insiders record

    Feldschuh Michael Richard (CEO & President) bought 2,000 shares of DXR ($19,500) (dated 25 May 2023)

  30. 26 May 2023Insiders record

    Goudie Joy S. (director) bought 300 shares of DXR ($2,925) (dated 25 May 2023)

  31. 20 Apr 2023Lobbying record

    DAXOR CORPORATION: lobbying engagement terminated (STRATEGIC MARKETING INNOVATIONS) (dated 1 Jan 2023)

  32. 19 Nov 2022Insiders record

    DesRosiers Caleb (director) bought 3,157 shares of DXR ($29,992) (dated 18 Nov 2022)

  33. 19 Nov 2022Insiders record

    Michel Robert J (Chief Financial Officer) bought 1,000 shares of DXR ($10,000) (dated 18 Nov 2022)

  34. 18 Apr 2022Lobbying record

    DAXOR CORPORATION: new lobbying registration (STRATEGIC MARKETING INNOVATIONS) (dated 24 Mar 2022)

  35. 24 Jan 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  36. 24 Jan 2022Filings record

    Director or officer change

  37. 20 Jan 2022Filings record

    Delisting notice or listing transfer

  38. 20 Apr 2021Insiders record

    Michel Robert J (CHIEF FINANCIAL OFFICER) bought 1,000 shares of DXR ($10,250) (dated 19 Apr 2021)

  39. 17 Apr 2021Insiders record

    Feldschuh Michael Richard (CEO & President) bought 4,200 shares of DXR ($43,386) (dated 16 Apr 2021)

  40. 1 Jul 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 66 entries; narrow the window or the kind of data to see older ones.

Not listed: 25 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000027367
Ticker
DXR
Domain
daxor.com
Hq location
TN|OAK RIDGE|37830 (1 unverified)
Lobbying client
daxor
Name
Daxor Corporation, EX-21.1, ex21_1.htm, Scientific Medical Systems Corp
Uei
EEAFMMXNTXA5, QGB8LQAGTAH8
  • Federal lobbying disclosures (LDA)6 records, 38 data points12 Jun 2015 to 31 Mar 2023
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)27 records7 Jul 2016 to 26 Jan 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)97 data points30 Dec 2009 to 22 Mar 2012
  • SEC Form 4 insider transactions53 records, 160 data points7 Apr 2016 to 19 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3764 data points2 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards2 records, 156 data points22 Oct 2007 to 17 Aug 2026